Latest News

Oct 2025

Delix gets FDA clearance for at-home use of its neuroplastogen in a Phase 2 study

Endpoints News

Oct 2025

Psychedelic-like therapy posts encouraging early data, as regulators clear at-home testing

STAT

Oct 2025

Delix Therapeutics Announces Positive Efficacy Data for DLX-001 (Zalsupindole) and FDA Clearance of Phase II Trial Design Featuring At-Home Administration

Press Release

Oct 2025

Delix Therapeutics Study Demonstrates that the Non‑Hallucinogenic Neuroplastogen Zalsupindole Promotes Neuroplasticity Like Ketamine and Psychedelics

Press Release

Dec 2024

Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting

Press Release

Dec 2024

Delix Therapeutics Announces Dosing of First Patient in Phase 1b Clinical Trial for DLX-001 in Major Depressive Disorder

Press Release

Aug 2024

FDA rejected MDMA-assisted PTSD therapy. Other psychedelics firms intend to avoid that fate

Science

Aug 2024

What Happens Now That The FDA Rejected Ecstasy-Assisted Therapy For PTSD? Experts Weigh In

Quartz

Jul 2024

Delix Plans Further Trials With Neuroplastogen After Positive Phase I Data

Yahoo Finance, GlobalData

Jun 2024

Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Loss

Press Release

May 2024

Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial

Press Release

Dec 2023

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

Press Release

Sep 2023

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Press Release

Sep 2023

Recognizing Inspiring Achievements From 2023: Delix nominated for Clinical Advance of the Year.

Biotech Week Boston

Jul 2023

The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

The Galien Foundation

Jun 2023

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

Press Release

Feb 2023

Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Press Release

Feb 2023

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Press Release

Nov 2022

Nature Biotechnology’s academic spinouts 2021

Nature Biotechnology

Sep 2022

Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association

Healthcare Businesswomen's Association (HBA)

Sep 2022

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Press Release

Sep 2022

Delix Therapeutics Expands World-Class Team with First Head of R&D

Press Release

Sep 2022

Taking The Tripping Out Of Psychedelic Medicine

Nature

Jul 2022

Accessibility Is Key for the Psychedelic Revolution

Pharmacy Times

May 2022

Psychoplastogens: Evolution of the psychedelic revolution

Nature

Mar 2022

Drug Companies Are Investing Big In Psychedelics, But Can They Engineer Out The Trip?

Chemical and Engineering News

Jan 2022

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Press Release

Jan 2022

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of

VICE

Dec 2021

Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders

Press Release

Sep 2021

Delix named Fierce Biotech's 2021 Fierce 15

Fierce Biotech

Jul 2021

Woman of the Week: Retsina Meyer, PhD

Pharma Voice

Mar 2021

Delix Therapeutics Names Mark Rus as Chief Executive Officer

Press Release